Journal of Translational Medicine Toll like Receptor-3 Ligand Poly-iclc Promotes the Efficacy of Peripheral Vaccinations with Tumor Antigen-derived Peptide Epitopes in Murine Cns Tumor Models

No abstract is available for this paper.

• Publication year

  year unknown

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunobiology

  2020cited by this paper
• Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.

  2006cited by this paper
• TLR3‐mediated signal induces proinflammatory cytokine and chemokine gene expression in astrocytes: Differential signaling mechanisms of TLR3‐induced IP‐10 and IL‐8 gene expression

  2006cited by this paper
• Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10.

  2006cited by this paper
• The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu.

  2006cited by this paper
• Delivery of Dendritic Cells Engineered to Secrete IFN-α into Central Nervous System Tumors Enhances the Efficacy of Peripheral Tumor Cell Vaccines: Dependence on Apoptotic Pathways1

  2005cited by this paper
• Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs.

  2005cited by this paper
• Defining the Antigen-Specific T-Cell Response to Vaccination and Poly(I:C)/TLR3 Signaling: Evidence of Enhanced Primary and Memory CD8 T-Cell Responses and Antitumor Immunity

  2005cited by this paper
• Anti-&agr;4 integrin therapy for multiple sclerosis: Mechanisms and rationale

  2005cited by this paper
• Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

  2005cited by this paper
• Faculty Opinions recommendation of Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease.

  2005cited by this paper
• Inherited disorders of human Toll‐like receptor signaling: immunological implications

  2005cited by this paper
• The Reciprocal Interaction of NK Cells with Plasmacytoid or Myeloid Dendritic Cells Profoundly Affects Innate Resistance Functions1

  2005cited by this paper
• EphA2 as a glioma-associated antigen: a novel target for glioma vaccines.

  2005cited by this paper
• TLR Signaling Tailors Innate Immune Responses in Human Microglia and Astrocytes1

  2005cited by this paper
• The cancer/testis genes: review, standardization, and commentary.

  2004cited by this paper
• Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors

  2004cited by this paper
• alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity.

  2004cited by this paper
• p38 MAPK activation controls the TLR3-mediated up-regulation of cytotoxicity and cytokine production in human NK cells.

  2004cited by this paper
• Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis

  2004cited by this paper
• Shaping of adaptive immune responses to soluble proteins by TLR agonists: A role for IFN‐α/β

  2004cited by this paper
• TLR Signaling: An Emerging Bridge from Innate Immunity to Atherogenesis1

  2004cited by this paper
• Microglia Initiate Central Nervous System Innate and Adaptive Immune Responses through Multiple TLRs1

  2004cited by this paper
• Differential regulation of innate and adaptive immune responses in viral encephalitis

  2004cited by this paper
• Delivery of Interferon-α Transfected Dendritic Cells into Central Nervous System Tumors Enhances the Antitumor Efficacy of Peripheral Peptide-Based Vaccines

  2004cited by this paper
• Does Toll-like receptor 3 play a biological role in virus infections?

  2004cited by this paper
• CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells.

  2004cited by this paper
• APC-Independent Activation of NK Cells by the Toll-Like Receptor 3 Agonist Double-Stranded RNA

  2004cited by this paper
• Expression and function of Toll-like receptor 3 in human astrocytes

  2004cited by this paper
• Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection.

  2004cited by this paper
• Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon

  2003cited by this paper
• Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model.

  2003cited by this paper
• Dendritic Cells Mediate NK Cell Help for Th1 and CTL Responses: Two-Signal Requirement for the Induction of NK Cell Helper Function 1

  2003cited by this paper
• Type I interferons produced by dendritic cells promote their phenotypic and functional activation.

  2002cited by this paper
• Progression of Armed CTL from Draining Lymph Node to Spleen Shortly After Localized Infection with Herpes Simplex Virus 11

  2002cited by this paper
• Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3

  2001cited by this paper
• CD8(+) T cells secreting type 2 lymphokines are defective in protection against viral infection.

  2000cited by this paper
• Interaction of α4-integrin with VCAM-1 is involved in adhesion of encephalitogenic T cell blasts to brain endothelium but not in their transendothelial migration in vitro

  2000cited by this paper
• THE BRAIN PARENCHYMA IS PERMISSIVE FOR FULL ANTI-TUMOUR CTL EFFECTOR FUNCTION, EVEN IN THE ABSENCE OF CD4+ T CELLS.

  2000cited by this paper
• Immune selection after antigen-specific immunotherapy of melanoma.

  1999cited by this paper
• Type I Interferons Keep Activated T Cells Alive

  1999cited by this paper
• The development of experimental autoimmune encephalomyelitis in the mouse requires alpha4-integrin but not alpha4beta7-integrin.

  1998cited by this paper
• Type I IFNs enhance the terminal differentiation of dendritic cells.

  1998cited by this paper
• Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study.

  1996cited by this paper
• Type 1 and type 2: a fundamental dichotomy for all T-cell subsets.

  1996cited by this paper
• Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines.

  1995cited by this paper
• A method for the combined staining of cells and fibers in the nervous system.

  1953cited by this paper

• Targeting the expansion of myeloid-derived suppressor cells in liver cirrhosis

  2024cites this paper
• ASP-2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of Chagas’ disease

  2023cites this paper
• How brain ‘cleaners’ fail: Mechanisms and therapeutic value of microglial phagocytosis in Alzheimer's disease

  2023cites this paper
• Phase I study of a novel therapeutic vaccine as perioperative treatment for patients with surgically resectable hepatocellular carcinoma: The YCP02 trial

  2023cites this paper
• Dendritic Cell Vaccination in Conjunction with a TLR Agonist Polarizes Interferon Immune Responses in Malignant Glioma Patients

  2023cites this paper
• Toll-like receptor agonists as cancer vaccine adjuvants

  2023cites this paper
• Peptide-Decorated Degradable Polycarbonate Nanogels for Eliciting Antigen-Specific Immune Responses

  2023cites this paper
• Establishment and validation of a novel prognostic model for lower-grade glioma based on senescence-related genes

  2022cites this paper
• Transient Lymph Node Immune Activation by Hydrolysable Polycarbonate Nanogels

  2022cites this paper
• Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas

  2021cites this paper
• Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma

  2021cites this paper
• Delivery of therapeutic oligonucleotides in nanoscale

  2021cites this paper
• IFN-γ- and IL-17-producing CD8+ T (Tc17-1) cells in combination with poly-ICLC and peptide vaccine exhibit antiglioma activity

  2021cites this paper
• A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy

  2021influential citation
• Vaccine Therapies for Cancer: Then and Now

  2021cites this paper
• Immunotherapeutic Peptide Vaccine Approaches to Glioma

  2021cites this paper
• Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma.

  2020cites this paper
• Immunological effects of adjuvants in subsets of antigen presenting cells of cancer patients undergoing chemotherapy

  2020cites this paper
• Tumor antigens in glioma.

  2020cites this paper
• Prostaglandin E2 in a TLR3- and 7/8-agonist-based DC maturation cocktail generates mature, cytokine-producing, migratory DCs but impairs antigen cross-presentation to CD8+ T cells

  2020cites this paper
• Lipo-Based Vaccines as an Approach to Target Dendritic Cells for Induction of T- and iNKT Cell Responses

  2020cites this paper
• Peptide Vaccine Combined Adjuvants Modulate Anti-tumor Effects of Radiation in Glioblastoma Mouse Model

  2020cites this paper
• Unique challenges for glioblastoma immunotherapy - Discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology.

  2020cites this paper
• Considerations when treating high-grade pediatric glioma patients with immunotherapy

  2020cites this paper
• Toll‐like receptors (TLRs) in cancer; with an extensive focus on TLR agonists and antagonists

  2020cites this paper
• Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies

  2020cites this paper
• Immunotherapy and radiation for high-grade glioma: a narrative review

  2020cites this paper
• The current state of immunotherapy for primary and secondary brain tumors: similarities and differences.

  2020cites this paper
• Strategies for Targeting SARS CoV-2: Small Molecule Inhibitors—The Current Status

  2020cites this paper
• Synergistic Toll-like Receptor 3/9 Signaling Affects Properties and Impairs Glioma-Promoting Activity of Microglia

  2020cites this paper
• Targeting Cellular and Tissue HIV Reservoirs With Toll-Like Receptor Agonists

  2019cites this paper
• Tailoring early-phase clinical trial design to address multiple research objectives

  2019cites this paper
• Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma

  2019cites this paper
• A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients

  2019cites this paper
• Microparticle Depots for Controlled and Sustained Release of Endosomolytic Nanoparticles

  2019cites this paper
• CXCL1 regulates neutrophil homeostasis in pneumonia-derived sepsis caused by Streptococcus pneumoniae serotype 3.

  2019cites this paper
• Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients.

  2019cites this paper
• Turning the corner on therapeutic cancer vaccines

  2019cites this paper
• Tanycytes: A rich morphological history to underpin future molecular and physiological investigations

  2019cites this paper
• Poly I:C-based rHBVvac therapeutic vaccine eliminates HBV via generation of HBV-specific CD8+ effector memory T cells

  2019cites this paper
• Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy

  2018cites this paper
• Local Immunotherapies of Cancer

  2018cites this paper
• Clec9A+ Dendritic Cells Are Not Essential for Antitumor CD8+ T Cell Responses Induced by Poly I:C Immunotherapy

  2018cites this paper
• Virus-Like Particle, Liposome, and Polymeric Particle-Based Vaccines against HIV-1

  2018cites this paper
• Combination and inducible adjuvants targeting nucleic acid sensors

  2018cites this paper
• Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial

  2018cites this paper
• Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment

  2018cites this paper
• Immunomodulation with Adjuvants and Cytokines

  2018cites this paper
• Physiopathology of Foetal Onset Hydrocephalus

  2018cites this paper
• Poly IC pretreatment suppresses B cell-mediated lupus-like autoimmunity through induction of Peli1

  2018cites this paper
• HIV-1 T cell epitopes targeted to Rhesus macaque CD40 and DCIR: A comparative study of prototype dendritic cell targeting therapeutic vaccine candidates

  2018cites this paper
• Influx and Efflux of Immune Cells in the Central Nervous System

  2017cites this paper
• Modulating the Cellular Immune Response of Oligonucleotides by Brush Polymer-Assisted Compaction.

  2017cites this paper
• Combinatorial treatment with polyI:C and anti-IL6 enhances apoptosis and suppresses metastasis of lung cancer cells

  2017cites this paper
• Use of adjuvants for immunotherapy

  2017cites this paper
• Explorer Differential modulation of immune response and cytokine profiles in the bursae and spleen of chickens infected with very virulent infectious bursal disease virus

  2017cites this paper
• Complex Consisting of β-Glucan and Antigenic Peptides with Cleavage Site for Glutathione and Aminopeptidases Induces Potent Cytotoxic T Lymphocytes.

  2017cites this paper
• Prioritization schema for immunotherapy clinical trials in glioblastoma

  2016cites this paper
• In situ vaccination for the treatment of cancer.

  2016cites this paper
• Cerebrospinal fluid levels of tumor necrosis factor alpha and aquaporin 1 in patients with mild cognitive impairment and idiopathic normal pressure hydrocephalus.

  2016cites this paper
• Developing immunotherapeutic strategies to target brain tumors

  2016cites this paper
• Assessment of combined vaccination and immune modulation as an anti-tumour therapy

  2016cites this paper
• Immunomodulation Within a Single Tumor Site to Induce Systemic Antitumor Immunity: In Situ Vaccination for Cancer

  2016cites this paper
• Vaccine adjuvants as potential cancer immunotherapeutics

  2016cites this paper
• Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas.

  2016cites this paper
• Biological Response Modifier in Cancer Immunotherapy.

  2016cites this paper
• Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study

  2016cites this paper
• Transgene-derived overexpression of miR-17-92 in CD8+ T-cells confers enhanced cytotoxic activity.

  2015cites this paper
• Fusion protein comprised of the two schistosomal antigens, Sm14 and Sm29, provides significant protection against Schistosoma mansoni in murine infection model

  2015cites this paper
• Immunomodulatory spherical nucleic acids

  2015cites this paper
• Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs.

  2015cites this paper
• Vaccine adjuvant uses of poly-IC and derivatives

  2015cites this paper
• Mechanisem of Action of PICKCa Adjuvant and Its Therapeutic Vaccines

  2015influential citation
• Mechanisem of Action of PICKCa Adjuvant and Its Therapeutic Vaccines

  2015cites this paper
• Identification of glioma-associated antigens for brain tumor immunotherapy

  2015cites this paper
• Understanding How the Subcommissural Organ and Other Periventricular Secretory Structures Contribute via the Cerebrospinal Fluid to Neurogenesis

  2015cites this paper
• A Research Note on Features of Water Vapor Sorption of Chitosan Medicinal Films

  2015cites this paper
• Cancer Vaccine Final IQP

  2015cites this paper
• In situ vaccination: Cancer immunotherapy both personalized and off‐the‐shelf

  2015cites this paper
• Biomedical insights into cell adhesion and migration—from a viewpoint of central nervous system tumor immunology

  2015cites this paper
• Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma

  2015cites this paper
• Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy

  2014cites this paper
• The use of dendritic cells for peptide-based vaccination in cancer immunotherapy.

  2014cites this paper
• An iron oxide nanocarrier for dsRNA to target lymph nodes and strongly activate cells of the immune system.

  2014cites this paper
• Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas.

  2014cites this paper
• Pediatric Phase II Trials of Poly-ICLC in the Management of Newly Diagnosed and Recurrent Brain Tumors

  2014cites this paper
• Combination of the two schistosomal antigens Sm14 and Sm29 elicits significant protection against experimental Schistosoma mansoni infection.

  2014cites this paper
• Advances in swine immunology help move vaccine technology forward.

  2014cites this paper
• Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma

  2014cites this paper
• One feature doesn't fit all: characterizing topological features of targets in signaling networks

  2014cites this paper
• Different exosome cargo from plasma/bronchoalveolar lavage in non‐small‐cell lung cancer

  2014cites this paper
• Induction of Robust Type-I CD8+ T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC

  2014cites this paper
• The Combination of Histone Deacetylase Inhibitors and Oncolytic Viruses for the treatment of High-grade Gliomas

  2014cites this paper
• Cancer Vaccines

  2014cites this paper
• Current Vaccine Trials in Glioblastoma: A Review

  2014cites this paper
• Dual Role of TLR 3 in Inflammation and Cancer Cell Apoptosis

  2013cites this paper
• An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma

  2013cites this paper
• Immune-Checkpoint Blockade and Active Immunotherapy for Glioma

  2013cites this paper
• Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts

  2013cites this paper
• Effect of Montanide and Poly-ICLC Adjuvant on Human Self/Tumor Antigen-Specific CD4+ T Cells in Phase I Overlapping Long Peptide Vaccine Trial

  2013cites this paper